



ABCDx SA. ANNOUNCES COMPLETION OF PRIVATE PLACEMENT.

Geneva, Switzerland, June 5, 2018 – ABCDx SA completes a first private financing round, raising significant seed funds to accelerate and progress clinical and commercial development of its pipeline of brain injury-associated diagnostic products.

ABCDx SA is a Swiss diagnostic research and product development company, developing and validating new diagnostic products based on its proprietary portfolio of blood biomarker technologies. These technologies enable clinical decisions to be made more quickly and with significantly lower expense for the majority of patients suffering the effects of brain injuries and stroke. Earlier decision-making has the potential to transform care for patients with earlier use of known life-saving drugs, as well as reducing the burden on hospital emergency departments in triaging patients. In the future, qualification of patients for new neuroprotective therapies is envisaged. ABCDx has offices in Geneva, Switzerland and Seville, Spain and has important research and clinical collaborations in Geneva, Barcelona and Seville.

ABCDx's recent seed round was oversubscribed and raised significant funds exclusively from local private investors in the greater Geneva area. The company will use the funds partly to initiate clinical trials for products enabling early decentralised triage of patients suffering traumatic brain injury, as well as establishing manufacturing and distribution channels for commercialization. In addition, the company expects to file for European regulatory approval of the first product in 2018.

Alan Cookson, Co-Founder and CEO of ABCDx SA. said: *"It is a privilege to welcome new private investors to share in ABCDx's adventure. This investment recognizes the value of ABCDx's patented technologies, the potential of our products and the quality of our team. The company can now complete its transition from a pre-clinical to clinical stage company. I am looking forward to working with ABCDx's first-class team and our development partners, as well as the company's Shareholders, to ensure the successful market introduction of products using ABCDx technology".*

Jean-Charles Sanchez, Co-Founder & CSO of ABCDx and co-inventor of the company's technologies at The University of Geneva said: *"ABCDx has assembled a group of outstanding professionals and strong partners who together will bring to the market technologies conceived and created by innovative research at The University of Geneva and at the Vall d'Hebron Institute of Research. I am proud that this academic research is now contributing to the creation of new jobs and inward investment to the Geneva area. These technologies will enable many more patients to benefit from best-in-class care for serious and debilitating brain illnesses".*



Joan Montaner, Co-Founder & CMO of ABCDx and co-inventor of the company's technologies at Vall d'Hebron Institute of Research, Barcelona said: *"It is a privilege to be part of this exciting step forward which I believe will transform the care that neurology professionals can provide for their patients. Often, we are frustrated at the delay imposed by traditional methods of diagnosis; The ABCDx technologies will allow us to intervene earlier resulting in many patients recovering more rapidly and more completely following brain injury. That this improved care can be enabled at lower cost is truly a disruptive change".*

ABCDx's technologies are protected by a portfolio of patent applications. These proprietary technologies enable identification of brain pathology and rapid selection for appropriate therapy even before the patient arrives in the emergency room. ABCDx develops products for its own pipeline, as well as partnering with selected companies to co-develop products utilizing ABCDx technologies in specified market segments.

For further information, please contact:

ABCDx SA

Alan Cookson

Chief Executive Officer

alan.cookson@abcdx.ch